Research
Hormonal
Bariatric surgery resolves Polycystic Ovary Syndrome (PCOS) symptoms, including menstrual irregularities and hirsutism, and improves fertility in obese women, largely through weight loss and hormonal normalization.
If you are obese and have PCOS, bariatric surgery can significantly improve your menstrual cycles, reduce excess hair growth, and increase your chances of conceiving. This is achieved through hormonal normalization and weight loss.
GoodSupportsHIGH confidence
Significant improvements in general sexual quality, functioning and hormonal levels after BS. An improvement in gonadal dysfunction in 82% of patients with a recovery in menstrual irregularities, 89% hirsutism resolution, and 50% achieve conception.
Why this rating
Supported by multiple prospective studies and meta-analyses, though heterogeneity exists.
Source
Metabolic and Endocrine Consequences of Bariatric Surgery
Isabel Cornejo‐Pareja et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00626
narrative_reviewCited 112×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery leads to long-term nutrient deficiencies (anemia, neuropathies, osteoporosis) due to malabsorption and reduced gastric acid, requiring lifelong monitoring and supplementation.Strong
- Bariatric surgery induces early, pronounced improvements in hepatic and peripheral insulin sensitivity and glycemic control that occur independently of significant weight loss, primarily through anatomical remodeling of the gastrointestinal tract.Good
- Bariatric surgery reverses obesity-associated secondary hypogonadism (MOSH) in men, leading to increased total and free testosterone levels and improved sexual function.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →